Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 16.01.2020 | 10:20

Aladdin Healthcare Technologies SE: Announces we have developed a prototype A.I powered data analysis platform for brain imaging.

DGAP-Media / 16.01.2020 / 10:20

Aladdin Healthcare Technologies SE: Announces we have developed a prototype A.I powered data analysis platform for brain imaging.
(BERLIN, Germany and LONDON, England) 16 January 2020 Aladdin Healthcare Technologies SE ("Aladdin"), a leading developer of next generation breakthroughs in age-related disease accelerated by the integration of leading science and A.I today announces we have developed a prototype A.I powered data analysis platform for brain imaging. 
Our technological breakthrough means the prototype can process brain imaging data with the assistance of deep learning models. The novel application that can solve a number of issues regarding Alzheimer's Disease (AD) data analysis and computer aided diagnosis (CAD) with multiple analytics solutions for early detection and patient management.
Currently within the healthcare industry, there are a several issues with brain data analysis software that is being used within hospitals, issues such as:
  • Limited functions requiring a significant amount of manual work and interventions.
  • Inaccurate single modality analysis and limited support for different types of data.
  • Limited connectivity and insecure databases.
Benefits for healthcare professionals and patients worldwide:
The following new features and attributes that the platform delivers, subject to CFDA and CE Mark approval, pave the way for a new generation of AD analytics tool that can significantly increase early stage diagnosis accuracy, workflow efficiency and lead to enhanced affordability.
The key features include:
  • Full and/or semi-automated analysis powered by recently developed A.I algorithms.
  • Full support for multimodal imaging data including Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI).
  • Highlighting the areas of potential disease, such as hippocampus area segmentation for Alzheimer's Disease, and other age-related diseases based on our A.I diagnosis model.
  • A cloud-based frontend and data privacy-preserved platform.
Aladdin's ability to combine multimodal data with specifically integrated A.I driven blood analysis makes for a novel approach to early diagnostics. Moreover, most other A.I approaches, currently available within the industry, reflect the reliance on utilising brain images as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple complexities that involve the disease and its underlying pathways.

Wade Menpes-Smith (Chairman)

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

End of Media Release

Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health

16.01.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


Northern Data AG: „Massiver Anstieg der Nachfrage durch Corona“

Die Frankfurter Northern Data AG (ISIN: DE000A0SMU87) hat sich innerhalb kürzester Zeit eine führende Position als Anbieter von Lösungen im High Performance Computing (HPC) erarbeitet. „Wir sprechen bereits heute von einem Markt im mittleren zweistelligen Milliardenbereich mit enormem Wachstum. Der gesamte Bereich explodiert nachfragemäßig vor unseren Augen“, erläutert CEO Aroosh Thillainathan im Pro Gigawatt peilt er einen Umsatz zwischen 400 und 500 Mio. Euro pro Jahr an, bei einer Bruttogewinnmarge von 40 bis 50 Prozent.


MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

SAP SE: SAP veröffentlicht vorläufige Ergebnisse für das erste Quartal und aktualisiert Ausblick für 2020

08. April 2020, 23:39

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie

Francotyp-Postalia Holding AG

Original-Research: Francotyp-Postalia Holding AG (von GSC Research GmbH): Kaufen

09. April 2020